– Interview with Phillip Sharp, Ph.D., Professor, David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology

Previous articleNanotechnology Advances
Next articleDxS to Provide a Companion Diagnostic for AstraZeneca’s NSCLC Drug